



General Assembly

Amendment

January Session, 2015

LCO No. 8244



Offered by:

SEN. LEONE, 27th Dist.

REP. BARAM, 15th Dist.

To: Subst. Senate Bill No. 28

File No. 329

Cal. No. 232

"AN ACT CONCERNING MANUFACTURER NAMES AND MEDWATCH REPORTING INFORMATION ON GENERIC DRUG CONTAINERS, THE ELECTRONIC PRESCRIPTION DRUG MONITORING PROGRAM AND PHARMACIST CHANGES TO PRESCRIPTION DRUGS DISPENSED TO CERTAIN PATIENTS."

1 Strike everything after the enacting clause and substitute the
2 following in lieu thereof:

3 "Section 1. Section 20-617 of the general statutes is repealed and the
4 following is substituted in lieu thereof (*Effective January 1, 2016*):

5 (a) Each pharmacist shall include on the label of each prescription
6 container: (1) The quantity of prescribed drug placed in such container,
7 in addition to any other information required by law, [;] and (2) a
8 prominently printed expiration date based on the manufacturer's
9 recommended conditions of use and storage that can be read and
10 understood by the ordinary individual. The expiration date required
11 pursuant to subdivision (2) of this [section] subsection shall be no later

12 than the expiration date determined by the manufacturer.

13 (b) In addition to the information required to be included on the
 14 label of each prescription container pursuant to subsection (a) of this
 15 section, each pharmacist shall include on the label of each prescription
 16 container or on the receipt or other similar packaging in which the
 17 prescription is contained for a drug sold only by generic name, as
 18 defined in section 20-14a, and not by brand name, as defined in said
 19 section: (1) The name of the manufacturer of the generic drug placed in
 20 the container, and (2) the Internet web site address and toll-free
 21 telephone number for the United States Food and Drug
 22 Administration's safety information and adverse event reporting
 23 program (MedWatch).

24 Sec. 2. (NEW) (*Effective July 1, 2015*) A pharmacist may not
 25 substitute a brand name drug product for a different brand name drug
 26 product unless specifically authorized, in writing, by the prescribing
 27 practitioner. For purposes of this section, "brand name" means the
 28 proprietary or trade name selected by a drug manufacturer and placed
 29 upon a drug product, its container, label or wrapping at the time of
 30 packaging."

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>January 1, 2016</i>	20-617
Sec. 2	<i>July 1, 2015</i>	New section